Drugs / Fusion-VAC-XS15
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05937295 | Sep 2023 → Sep 2026 overdue | fibrolamellar hepatocellular carcinoma | University Hospital Tuebingen | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Fusion-VAC-XS15 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05937295 ↗ |
| Route | Subcutaneous | “Two doses of the DNAJB1-PRKACA fusion-based neoepitope vaccine Fusion-VAC-XS15 will be applied subcutaneously (s.c.)” PMID 38606105 ↗ Mar 2024 |